More Emyria Ltd news
Emyria LtdASX: EMD

Further positive MDMA analogue screening results received

May 9, 2022 at 10:59 PM EDT · Issued by Emyria Ltd

Filed with ASX · May 9, 2022 at 10:59 PM EDT

On 6ix: 6ix.com/news/further-positive-mdma-analogue-screening-results-received

Emyria Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Emyria Ltd on 6ix

Story so far

  • Emyria grows its novel MDMA-analogue libraryFeb 22, 2022
  • Positive initial MDMA-analogue screening resultsDec 8, 2021
  • MDMA Analogue Development MilestoneOct 19, 2021

Earlier from Emyria

  • Broker Briefing PresentationMar 24, 2022
  • Emyria launches second ultra-pure CBD capsuleMar 16, 2022
  • Recruitment commenced for EMD-RX5 Phase 1 StudyMar 8, 2022
  • Ethics approval received for EMD-RX5 Phase 1 StudyMar 3, 2022
  • Emyria grows its novel MDMA-analogue libraryFeb 21, 2022

Later from Emyria

  • EMD-RX5 demonstrates excellent safety and bioavailabilityMay 24, 2022
  • Emyria expands MDMA analogue program with UWAMay 31, 2022
  • Emyria expands drug candidate library inspired by MDMAJul 17, 2022
  • Appendix 4C - QuarterlyJul 27, 2022
  • Preclinical studies initiated for MDMA-inspired analoguesAug 4, 2022
All Emyria news releases↗

Follow Emyria into a list and get an email when it puts out news.

Follow Emyria
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer